Akebia Therapeutics, Inc. provided Net product revenue guidance for the fiscal year 2022. for the period, the company expects the Net product revenue for Auryxia of $165 million $170 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.12 USD | +4.67% | +1.82% | -9.68% |
09/05 | Transcript : Akebia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
09/05 | Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q1 Revenue $32.6M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.68% | 23Cr | |
+11.60% | 11TCr | |
-4.68% | 2.43TCr | |
-0.55% | 2.2TCr | |
-9.00% | 1.82TCr | |
-42.12% | 1.64TCr | |
-17.47% | 1.56TCr | |
+2.77% | 1.36TCr | |
+34.58% | 1.23TCr | |
+77.64% | 887.31Cr |
- Stock Market
- Equities
- AKBA Stock
- News Akebia Therapeutics, Inc.
- Akebia Therapeutics, Inc. Provides Net Product Revenue Guidance for the Fiscal Year 2022